News

The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry

BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed rate (ABR) through 12 months on prophylaxis treatment with marstacimab, an investigational, novel subcutaneous

Under the deal, OncoImmune shareholders will be eligible to secure sales-based payments and payments contingent on the achievement of certain regulatory milestones. Recently, the biopharmaceutical company announced positive

The high-level results from an interim analysis, including 131 Covid-19, have shown no hospitalisations or severe cases of the disease in participants receiving the vaccine. AZD1222, co-invented by

The randomized, open label, multi-center study will enroll up to 100 non-hospitalized patients who have a positive SARS-CoV-2 test and are symptomatic to assess the antiviral activity, safety,

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) target date of May 21, 2021. “The FDA’s acceptance of our BLA and granting of priority review

The companies have submitted a request to the FDA to secure FDA EUA status for BNT162b2 mRNA vaccine candidate against SARS-CoV-2. The Covid-19 vaccine is expected to be

“We are encouraged by the European Commission’s and European Medicines Agency’s recognition of the benefit that zanidatamab can provide in the treatment of HER2-expressing gastric cancers as we

ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation.1,2 As